Last week, Sarah Cannon, our global cancer institute, and HCA Midwest Health, Kansas City's largest health care network, announced that they have expanded their cancer collaboration through clinical research. By joining a global research network, HCA Midwest Health now offers greater access to clinical trials for those facing cancer in the Kansas City area.
“Clinical trials are an integral part of advancing the standard of cancer care, as today's trials are tomorrow's cutting-edge treatments,” said Dr. Howard A. “Skip” Burris, III, president of clinical operations and chief medical officer at Sarah Cannon. “By expanding our partnership, we can provide patients in Kansas City with access to the latest treatments in the comfort of their doctors, family and friends close to home.”
Patients can access clinical trials throughout the HCA Midwest health system. The initial strategic research sites where Sarah Cannon clinical trials will take place in the coming weeks include the HCA Healthcare-affiliated Menorah Medical Center and the Medical Research Center. Additional locations are planned to launch in the near future.
Since 2014, HCA Midwest Health and Sarah Cannon have partnered to promote cancer services in Kansas City. Sarah Cannon Research Institute at HCA Midwest Health will be supported and complemented by the system's seven hospitals, Belton Regional Medical Center, Centerpoint Medical Center, Lafayette Regional Health Center, Lee's Summit Medical Center, Menorah Medical Center, Overland Park Regional Medical Center and Research Medical Center, as well as from numerous cancer care service locations located in communities throughout the region.
Learn more about the HCA Midwest Health Clinical Research Program here.
